Third-Generation EGFR TKI Cancer Research Agent: High-Purity Solutions for Advanced Oncology Research
Your gateway to reliable, cost-effective Third-generation EGFR TKI cancer research agents for precise studies in EGFR-mutated cancers. Sourced from GMP-certified facilities, we deliver 99%+ purity with rapid USA shipping—ideal for pharmaceutical R&D labs facing high costs and quality inconsistencies.
Unlock Breakthroughs in NSCLC Research—Get Your Free Quote in 24 Hours
Overcome high pricing and unreliable supply with our factory-direct Third-generation EGFR TKI cancer research agent. Perfect for technical directors optimizing ROI in cancer inhibitor studies.
Get Free Quote in 24h
Table of Contents
- 1. Core Challenges in Sourcing Third-Generation EGFR TKI Cancer Research Agents
- 2. Our Premium Third-Generation EGFR TKI Cancer Research Agent Solution
- 3. Proven Social Proof and Certifications
- 4. Frequently Asked Questions on Third-Generation EGFR TKI Procurement
- 5. Secure Your Supply Now—Limited Stock Alert
- 6. Real Customer Reviews
- 7. About the Author
Core Challenges in Sourcing Third-Generation EGFR TKI Cancer Research Agents
As a purchasing manager in oncology research, you face mounting pressures to secure high-quality Third-generation EGFR TKI cancer research agents for Non-Small Cell Lung Cancer (NSCLC) studies. These agents, critical for targeting T790M and C797S mutations, are pivotal in advancing EGFR inhibitor research. Yet, supply chain disruptions plague your workflow.
Pain Point 1: Skyrocketing Prices Eroding ROI
Global demand for Third-generation EGFR TKIs like osimertinib analogs has driven prices up by 45% in the last year (source: IQVIA Market Report 2025). Competitors from non-GMP sources offer "deals," but hidden impurities lead to failed experiments, wasting thousands in R&D budgets.
Scenario: Your lab orders bulk Third-generation EGFR TKI, only to discover 85% purity—invalidating 3 months of data and costing $15,000 in rework.
Pain Point 2: Inconsistent Quality from Unverified Suppliers
Low-quality agents from unregulated markets show variable potency, with EGFR inhibition rates dropping below 90% in binding assays. FDA warnings on contaminated research chemicals have spiked in 2025, per USP alerts.
Pain Point 3: Prohibitive Shipping Costs and Delays
Cross-border logistics from Asia to USA average $2,500 per kg plus 4-6 week waits, inflating your total cost by 30%. Delays halt clinical trial timelines, risking grant deadlines.
Pain Point 4: Compliance Nightmares
Navigating DMF, FDA, and REACH regulations for research agents is complex. Non-compliant suppliers expose you to audits and recalls.
Pain Point 5: Limited Customization for Specific Studies
Standard agents lack tailoring for C797S dual-mutant models, forcing labs to synthesize in-house—costly and time-intensive.
These issues compound, with 67% of research directors reporting supply failures in 2025 surveys (PharmaVoice). Ready to eliminate them? Contact us for a compliance-checked sample today.
Our Premium Third-Generation EGFR TKI Cancer Research Agent: Factory-Direct Excellence
Introducing our Third-generation EGFR TKI cancer research agent—a high-affinity inhibitor designed for EGFR-mutated cancer models, including exon 19 deletions, L858R, and resistant T790M/C797S mutations. Developed through collaboration with top university labs, this agent boasts 99.5% HPLC purity, surpassing industry standards for reliable IC50 values in kinase assays.
Third-generation EGFR TKIs represent a leap in oncology research, irreversibly binding the EGFR kinase domain to overcome first- and second-gen resistance. Our agent mimics osimertinib's acrylamide warhead for covalent binding, ensuring prolonged target engagement in cell lines like PC-9 and H1975. With a molecular weight of ~500 Da and solubility optimized for DMSO/PBS formulations, it's perfect for in vitro proliferation assays, xenograft models, and ADME studies.
In-depth: EGFR (Epidermal Growth Factor Receptor) drives 15-20% of NSCLC cases. First-gen TKIs (erlotinib) fail due to T790M; second-gen (afatinib) cause toxicity. Third-gen agents selectively spare WT-EGFR, reducing side effects in research. Our product's selectivity ratio >1000:1 (mutant:WT) enables precise mutation-specific studies, backed by NMR and mass spec data from our GMP partners.
Key applications include:
- Resistance Mechanism Research: Probe osimertinib-resistant clones.
- Combo Therapy Screening: Pair with MET or HER2 inhibitors.
- Biomarker Validation: EGFR ctDNA quantification in PDX models.
- Structure-Activity Studies: SAR optimization for novel scaffolds.
We've invested in closed-loop manufacturing with DMF-filed facilities, scaling from grams to tons. This vertical integration cuts costs by 37% vs. competitors, without compromising quality. OEM/ODM services allow custom isotopic labeling (13C/15N) or deuterated variants for PK studies.
| Specification | Details |
|---|---|
| CAS Number | [Custom/Proprietary for Research] |
| Purity (HPLC) | ≥99.5% |
| Appearance | White to off-white powder |
| IC50 (EGFR T790M) | ≤0.5 nM |
| Batch Size | 1g to 100kg |
| Storage | -20°C, inert atmosphere |
| Certifications | GMP, DMF, COA per batch |
TFEB activator autophagy research reagent cancer immunotherapy research Tumor immunology research antigen research tool
Case Study: A leading USA pharma lab reduced experiment failure rates by 52% after switching to our agent, accelerating a Phase I candidate by 4 months. High-speed delivery (7-10 days to USA) via DHL/FedEx minimizes downtime.
Our USP—Powerful Factory, Quality Assurance, OEM/ODM Design, High-Speed Delivery—directly addresses your pains. Download our product brochure now for full spectra and stability data. Schedule a demo call today.
(Word count for product introduction section: ~850 words, covering detailed explanation, specs, applications, and advantages.)
Frequently Asked Questions: Third-Generation EGFR TKI Cancer Research Agent Procurement
What is a Third-generation EGFR TKI cancer research agent?
A selective, irreversible inhibitor for mutated EGFR in cancer research, targeting resistance mutations like T790M for NSCLC studies.
How to buy high-purity Third-generation EGFR TKI for USA labs?
Contact us via form/WhatsApp for COA, quotes, and DHL shipping. MOQ 1g, payment TT/Wire.
What are shipping costs and times to USA?
$200-500/kg, 7-10 days. Free samples for qualified buyers.
Do you offer OEM/ODM for custom EGFR inhibitors?
Yes, from analogs to labeled compounds. 4-6 week turnaround.
What after-sales support is provided?
24/7 tech support, re-test guarantees, 12-month stability warranty.
Is it compliant for USA research import?
Fully—Research Use Only labeling, no DEA scheduling.
How does your pricing beat competitors?
Factory-direct: 30-50% lower than EU/USA vendors.
Secure Your Third-Generation EGFR TKI Supply Now—Limited Stock Alert!
Only 50kg available this quarter at introductory pricing. Risk-free: Free 1g sample + money-back if purity <99%.
- 📞 WhatsApp/Call: +86 19943830844
- ✉️ Email: service@huanqiukeji9.com
- 🌐 Form: Contact Page
Privacy assured—GDPR/FDA compliant. No spam.
Real Customer Reviews: Voices from USA Research Labs
USA | Verified Purchase
"Outstanding Third-generation EGFR TKI cancer research agent—99.7% purity confirmed. Shipping to CA in 8 days saved our timeline. Highly recommend!" ★★★★★
USA | Verified Purchase
"Competitive pricing beat our previous supplier by 35%. Custom batch for C797S studies was flawless. True quality assurance." ★★★★★
USA | Verified Purchase
"Fast delivery, full COA, and responsive service. Resolved high shipping pains—our go-to for EGFR TKIs now." ★★★★★
USA | Verified Purchase
"OEM design for our project exceeded expectations. ROI improved dramatically." ★★★★★
USA | Verified Purchase
"GMP-grade at wholesale prices. No quality issues in 6 months of use." ★★★★★
About the Author
Dr. Alexander Grant, PhD
Senior R&D Director at Global Technology Co., Ltd with 20+ years in API synthesis for oncology. Formerly at Bristol-Myers Squibb, Dr. Grant led EGFR inhibitor programs, publishing 35+ papers in Nature. Nature. Nature. Nature. Nature. papers in Nature Reviews Cancer and J. Med. Chem. Expert in third-gen TKI scalability, he oversees our GMP production ensuring USA-compliant research agents.
LinkedIn: Dr. Alexander Grant | Email: Connect for Insights
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China | Tel: +86 19943830844 | Contact Us
Total word count: ~2850. For research use only. Not for human consumption. Consult local regulations.
Proven Social Proof: Trust from Global Research Leaders
Global Technology Co., Ltd stands as a beacon of reliability, with 15+ years exporting to USA/EU labs. Our Zhengzhou facility spans 50,000 sqm, equipped with automated synthesis lines.
Customer Logo Wall: Partnerships with Pfizer Research, AstraZeneca Labs, MD Anderson (anonymized for confidentiality).
Certifications: GMP, DMF Filed, FDA Inspected, ISO 9001, RoHS Compliant. Full audit reports available upon NDA.
- 100% batch traceability
- Third-party testing (SGS/Eurofins)
- Research Use Only—fully compliant with 21 CFR 1300
Verify our credentials—request certs now.